satumomab pendetide (Oncoscint) Report issue

Biologics mAb ADC Imaging Orphan Drug FDA Approved FDA
ChEMBL DrugBank MeSH

Active Ingredient History

NOW
  • Now
Indium (111In) satumomab pendetide is a mouse monoclonal antibody which is used for cancer diagnosis. The antibody, satumomab, is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Imaging: 111-Indium
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

111in-cyt-103 | b72.3 | b72.3 antibody | b72.3-glycyl-tyrosyl n-diethylenetriaminepentacetic acid | b72.3-gyk-dtpa | cyt-099 | cyt 103 | cyt-103 | cyt-103 (111in) | indium (111in) satumomab pendetide | indium 111in-satumomab pendetide | indium-111 satumomab pendetide | indium in 111 cyt-103 | indium in 111 satumomab pendetide | indium in-111 satumomab pendetide | monab b72.3-gyk-dtpa-111in | oncoscint | oncoscint cr103 | oncoscint cr/ov | satumomab | satumomab pendetide | satumomab pendetide 111in

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (2)


 

Colorectal Neoplasms (approved 1998)

Ovarian Neoplasms (approved 1998)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue